Xtl Biopharmaceuticals (XTLB) Consolidated Net Income (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Consolidated Net Income of -$1.3 million for Q4 2024, up 4.74% year-on-year from -$1.2 million in Q1 2024, and down 161.84% on a QoQ basis from $2.0 million in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Consolidated Net Income (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Consolidated Net Income for 16 consecutive years, with -$1.3 million the latest figure, recorded in Q4 2024.
- Quarterly Consolidated Net Income rose 4.74% year-over-year to -$1.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 206.16% YoY) and the FY2025 annual result came in at -$0.01, up 100.0% from the prior year.
- Consolidated Net Income fell to -$1.3 million in Q4 2024 per XTLB's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Consolidated Net Income for XTLB reached as high as $2.0 million in Q3 2024 and fell as low as -$1.8 million in Q4 2021.
- A 5-year average of -$33297.7 and a median of -$224500.0 in 2020 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2021 — Consolidated Net Income jumped 689.86% — and 2023, when it sank 281.62%.
- Year by year, Consolidated Net Income stood at $1.9 million in 2020, then sank by 194.72% to -$1.8 million in 2021, then rose by 13.57% to -$1.5 million in 2022, then gained by 13.36% to -$1.3 million in 2023, then advanced by 4.74% to -$1.3 million in 2024.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$1.3 million, $2.0 million, and -$704000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | -704,000.00 |
| Mar 31, 2024 | 485,000.00 |
| Dec 31, 2023 | -1.33 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | -364,000.00 |
| Mar 31, 2023 | -919,000.00 |
| Dec 31, 2022 | -1.54 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | -285,000.00 |
| Mar 31, 2022 | 506,000.00 |
| Dec 31, 2021 | -1.78 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | -303,000.00 |
| Mar 31, 2021 | -232,000.00 |
| Dec 31, 2020 | 1.88 Mn |
| Sep 30, 2020 | -217,000.00 |
| Jun 30, 2020 | -217,000.00 |
| Mar 31, 2020 | 173,000.00 |